Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.90 |
---|---|
High | 25.00 |
Low | 24.90 |
Bid | 24.85 |
Offer | 25.00 |
Previous close | 24.95 |
Average volume | 23.09k |
---|---|
Shares outstanding | 10.25m |
Free float | 4.90m |
P/E (TTM) | 57.94 |
Market cap | 256.22m EUR |
EPS (TTM) | 0.4315 EUR |
Data delayed at least 15 minutes, as of Sep 20 2024 16:35 BST.
More ▼
Announcements
- EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
- EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DU TEST GÉNOMIQUE ENDOPREDICT® AUPRÈS DE MYRIAD GENETICS
- Eurobio Scientific : suspension du contrat de liquidité
- Eurobio Scientific: CONCLUSION D’UN ACCORD ENTRE EUROBIO SCIENTIFIC ET UN CONSORTIUM MENÉ PAR L’ÉQUIPE D’ENTREPRENEURS ET DIRIGEANTS D’EUROBIO SCIENTIFIC, IK PARTNERS ET NEXTSTAGE AM EN VUE DU DÉPÔT D’UNE OFFRE PUBLIQUE D’ACHAT VOLONTAIRE A
- EUROBIO SCIENTIFIC: CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC'S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO FILE A VOLUNTARY TENDER OFFER AT A PRICE
- Eurobio Scientific : PREMIER SEMESTRE 2024, UN SOLIDE DEBUT D’EXERCICE DANS UN CONTEXTE INCERTAIN // PROJET D’OFFRE PUBLIQUE
- Eurobio Scientific: FIRST HALF 2024, A SOLID START TO THE FINANCIAL YEAR IN AN UNCERTAIN ENVIRONMENT // PROPOSED TENDER OFFER
- EUROBIO SCIENTIFIC : CALENDRIER DES PUBLICATIONS FINANCIÈRES DU 2EME SEMESTRE
- Eurobio Scientific : bilan semestriel du contrat de liquidité
- EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
More ▼